Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks

Journal of Diabetes Investigation

Volumn 3, Issue 2, 2012, Pages 175-178

  Hamaguchi, Tomoya ^a   Koga, Masafumi ^c   Murai, Jun ^c   Saito, Hiroshi ^c   Tamada, Daisuke ^b   Kurebayashi, Shogo ^b   Katsuno, Tomoyuki ^a   Miyagawa, Jun Ichiro ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Nishinomiya Municipal Central Hospital   (Japan)

^c Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

Author keywords

Glycated albumin; HbA1c; Incretin

Indexed keywords

GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INCRETIN; SITAGLIPTIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84859114184     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00167.x     Document Type: Article

References (22)

1. Cohen MP. Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy? J Diabetes Complications 1998; 2: 214-217.
2. Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295: 417-420.
3. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978; 20: 21-27.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
6. Koga M, Kasayama S. Clinical usefulness of glycated albumin as another glycemic control marker. Endocr J 2010; 57: 751-762.
7. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18: 440-447.
8. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986; 261: 13542-13425.
9. Takahashi S, Uchino H, Shimizu T, et al. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007; 54: 139-144.
10. Yoshiuchi K, Matsuhisa M, Katakami N, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008; 55: 503-507.
11. Suwa T, Ohta A, Matsui T, et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 2010; 57: 135-140.
12. Koga M, Hashimoto K, Murai J, et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011; 412: 253-257.
13. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
14. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-767.
15. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
16. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
17. Schnedl WJ, Lahousen T, Wallner SJ, et al. Silent hemoglobin variants and determination of HbA1C with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem 2005; 38: 88-91.
18. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
19. Kouzuma T, Usami T, Yamakoshi M, et al. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 2002; 324: 61-71.
20. Kohzuma T, Koga M. Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus. Mol Diagn Ther 2010; 14: 49-51.
21. Koga M, Murai J, Saito H, et al. Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes. J Diabetes Invest 2011; 2: 304-309.
22. Kanazu S, Horie Y, Narukawa M, et al. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 813-818.